MG 4101

Drug Profile

MG 4101

Alternative Names: Allogeneic NK cells; MG-401; MG4101

Latest Information Update: 09 Dec 2016

Price : $50

At a glance

  • Originator Green Cross
  • Developer Green Cross; Samsung Medical Center; Seoul National University Hospital
  • Class Antineoplastics
  • Mechanism of Action Cell death stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Hepatocellular carcinoma; Solid tumours
  • Phase I Lymphoma

Most Recent Events

  • 30 Sep 2016 Green Cross LabCell Corporation initiates enrolment in a phase II trial for Hepatocellular carcinoma in South Korea (NCT02854839)
  • 02 Jun 2016 Samsung Medical Center completes a phase II trial in Solid tumours in South Korea (NCT01807468)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top